Bibliography
- Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci 2002;115:3991-4000
- Robb VA, Li W, Gascard P, et al. Identification of a third Protein 4.1 tumor suppressor, protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 2003;13:191-202
- Peng S, Fan S, Li X, et al. The expression of ezrin in NPC and its interaction with NGX6, a novel candidate suppressor. Cancer Sci 2007;98:341-9
- Haase D, Meister M, Muley T, et al. FRMD3, a novel putative tumour suppressor in NSCLC. Oncogene 2007;26:4464-8
- Li Q, Wu M, Wang H, et al. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 2008;261:55-63
- Bruce B, Khanna G, Ren L, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007;24:69-78
- Parra M, Gascard P, Walensky LD, et al. Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. J Biol Chem 2000;275:3247-55
- Han BG, Nunomura W, Takakuwa Y, et al. Protein 4.1R core domain structure and insights into regulation of cytoskeletal organization. Nat Struct Biol 2000;7:871-5
- Taylor-Harris PM, Felkin LE, Birks EJ, et al. Expression of human membrane skeleton protein genes for protein 4.1 and βIIΣ2-spectrin assayed by real-time RT-PCR. Cell Mol Biol Lett 2005;10:135-49
- Gimm JA, An X, Nunomura W, Mohandas, N. Functional characterization of spectrin-actin-binding domains in 4.1 family of proteins. Biochemistry 2002;41:7275-82
- Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis 2001;8:266-78
- Calinisan V, Gravem D, Chen RP, et al. New insights into potential functions for the protein 4.1 superfamily of proteins in kidney epithelium. Front Biosci 2006;11:1646-66
- Kuns R, Kissil JL, Newsham IF, et al. Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene 2005;24:6502-15
- Ramez M, Blot-Chabaud M, Cluzeaud F, et al. Distinct distribution of specific members of protein 4.1 gene family in the mouse nephron. Kidney Int 2003;63:1321-37
- Diakowski W, Grzybek M, Sikorski AF. Protein 4.1, a component of the erythrocyte membrane skeleton and its related homologue proteins forming the protein 4.1/FERM superfamily. Folia Histochem Cytobiol 2006;44:231-48
- Yageta M, Kuramochi M, Masuda M, et al. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 2002;62:5129-33
- Yu T, Robb VA, Singh V, et al. The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J 2002;365:783-9
- Singh V, Miranda TB, Jiang W, et al. DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. Oncogene 2004;23:7761-71
- Jiang W, Roemer ME, Newsham IF. The tumor suppressor DAL-1/4.1B modulates protein arginine N-methyltransferase 5 activity in a substrate-specific manner. Biochem Biophys Res Commun 2005;329:522-30
- McCarty JH, Cook AA, Hynes RO. An interaction between αvβ8 integrin and Band 4.1B via a highly conserved region of the Band 4.1 C-terminal domain. Proc Natl Acad Sci USA 2005;102:13479-83
- Tran Y, Benbatoul K, Gorse K, et al. Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene 1998;17:3499-505
- Lukeis R, Ball D, Irving L, et al. Chromosome abnormalities in non-small cell lung cancer pleural effusions: cytogenetic indicators of disease subgroups. Genes Chromosomes Cancer 1993;8:262-9
- Tran YK, Bogler O, Gorse KM, et al. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res 1999;59:35-43
- Kikuchi S, Yamada D, Fukami T, et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 2005;11:2954-61
- Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495-500
- Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004;70:183-202
- Ng HK, Lau KM, Tse JY, et al. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 1995;37:764-73
- Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997;49:267-70
- Nunes F, Shen Y, Niida Y, et al. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 2005;162:135-9
- Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59:872-9
- Surace EI, Lusis E, Murakami Y, et al. Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. J Neuropathol Exp Neurol 2004;63:1015-27
- Singh PK, Gutmann DH, Fuller CE, et al. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol 2002;15:526-31
- Rajaram V, Gutmann DH, Prasad SK, et al. Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol 2005;18:991-7
- Kittiniyom K, Gorse KM, Dalbegue F, et al. Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res 2001;3:192-8
- Charboneau AL, Singh V, Yu T, Newsham IF. Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer 2002;100:181-8
- Heller G, Geradts J, Ziegler B, et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 2007;103:283-91
- Yamada D, Kikuchi S, Williams YN, et al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer 2006;118:916-23
- Ohno N, Terada N, Murata S, et al. Immunolocalization of protein 4.1B/DAL-1 during neoplastic transformation of mouse and human intestinal epithelium. Histochem Cell Biol 2004;122:579-86
- Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-39
- Tsujiuchi T, Sugata E, Masaoka T, et al. Expression and DNA methylation patterns of Tslc1 and Dal-1 genes in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Cancer Sci 2007;98:943-8
- Terada N, Ohno N, Yamakawa H, et al. Protein 4.1B in mouse islets of Langerhans and beta-cell tumorigenesis. Histochem Cell Biol 2003;120:277-83
- Schulz WA, Alexa A, Jung V, et al. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 2007;6:14. Published online 5 February 2007, doi:10.1186/1476-4598-6-14
- Wong SY, Haack H, Kissil JL, et al. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 2007;104:12784-9
- Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101:811-6
- Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8
- Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9
- Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9
- Yi C, McCarty JH, Troutman SA, et al. Loss of the putative tumor suppressor band 4.1B/Dal1 gene is dispensable for normal development and does not predispose to cancer. Mol Cell Biol 2005;25:10052-9
- Robb VA, Li W, Gutmann DH. Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression. Oncogene 2004;23:3589-96
- Darling DL, Yingling J, Wynshaw-Boris A. Role of 14-3-3 proteins in eukaryotic signaling and development. Curr Top Dev Biol 2005;68:281-315
- Tang J, Gary JD, Clarke S, Herschman HR. PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem 1998;273:16935-45
- Aletta JM, Cimato TR, Ettinger MJ. Protein methylation: a signal event in post-translational modification. Trends Biochem Sci 1998;23:89-91
- McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell 2001;106:5-8
- Fukuhara H, Kuramochi M, Fukami T, et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 2002;93:605-9
- Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 2005;96:543-52
- Fukuhara H, Masuda M, Yageta M, et al. Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg. Oncogene 2003;22:6160-5
- Mao X, Seidlitz E, Ghosh K, et al. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res 2003;63:7979-85
- Jiang W, Newsham IF. The tumor suppressor DAL-1/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells. Mol Cancer 2006;5:4. Published online 18 January 2006, doi:10.1186/1476-4598-5-4
- Mao X, Seidlitz E, Truant R, et al. Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene 2004;23:5632-42
- Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH. Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene 2005;24:1946-57
- Gerber MA, Bahr SM, Gutmann DH. Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res 2006;66:5295-303
- Cavanna T, Pokorna E, Vesely P, et al. Evidence for protein 4.1B acting as a metastasis suppressor. J Cell Sci 2007;120:606-16
- Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95
- Ahmad A, Hart IR. Mechanisms of metastasis. Crit Rev Oncol Hematol 1997;26:163-73
- Kittiniyom K, Mastronardi M, Roemer M, et al. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer 2004;40:190-203
- Fandy TE, Carraway H, Gore SD. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J 2007;13:40-8
- Pariente N, Morizono K, Virk MS, et al. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 2007;15:1973-81
- Li X, Liu YH, Zhang YP, et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007;13:5463-73
- Ueda K, Kawashima H, Ohtani S, et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 2006;66:9682-90
- Lu C, Sepulveda CA, Ji L, et al. Systemic therapy with tumor suppressor FUS1-nanoparticles for stage IV lung cancer [abstract # LB-348]. American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14 – 18; Los Angeles, CA: Philadelphia (PA)